DOI QR코드

DOI QR Code

Successful Arterial Thromboembolism Therapy in a Cat with Recombinant Tissue Plasminogen Activator Using an Accelerated Dosing Protocol

  • Cho, Yoo-Ra (College of Veterinary Medicine, Chungnam National University) ;
  • Seo, Do-Hyun (College of Veterinary Medicine, Chungnam National University) ;
  • Choi, Ho-Jung (College of Veterinary Medicine, Chungnam National University) ;
  • Song, Kun-Ho (College of Veterinary Medicine, Chungnam National University) ;
  • Seo, Kyoung-Won (College of Veterinary Medicine, Chungnam National University)
  • 투고 : 2017.05.11
  • 심사 : 2017.08.11
  • 발행 : 2017.08.31

초록

An 8-year old female Korean Short Hair cat with a history of paralysis of both hind limbs less than 1 hour before admission was referred. On physical examination, the left hind limb was cold and there was no pulsation or mobility. On abdominal ultrasound examination, a thrombus 8 mm in length was found at the aortic bifurcation. The patient was diagnosed with hypertrophic cardiomyopathy (HCM) and cardiogenic pulmonary edema through radiologic evaluation and echocardiography. A tissue plasminogen activator (tPA) was applied intravenously using an accelerated dosing protocol (1 mg administered intravenously [IV] bolus, 2.5 mg IV over 30 min, 1.5 mg IV over 1 h) to treat the feline arterial thromboembolism. Within 12 h after administration of tPA, pulsation and mobility of both hind limbs were normal, without any noticeable complications. Clopidogrel was prescribed to prevent additional thrombus formation, and pimobendan, benazepril, and furosemide were prescribed for administration at home. The patient was discharged and survived 377 days.

키워드

참고문헌

  1. Bonagura JD, Twedt DC. Therapy for feline thromboem-bolism. In: Kirk's Current Veterinary Therapy X. St. Louis: Elsevier Health Sciences 2013; 295-302.
  2. Goldhaber SZ. Treatment of pulmonary thromboembolism. Intern Med J 1999; 38: 620-625. https://doi.org/10.2169/internalmedicine.38.620
  3. Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis: an international multicenter randomized trial. Chest 1994; 106: 718-724. https://doi.org/10.1378/chest.106.3.718
  4. Goldhaber SZ, Feldstein ML, Sors H. Two trials of reduced bolus alteplase in the treatment of pulmonary embolism: an overview. Chest 1994; 106: 725-726. https://doi.org/10.1378/chest.106.3.725
  5. Gordon SG, Cote E. Pharmacotherapy of feline cardiomyopathy: Chronic management of heart failure. J Vet Cardiol 2015; 17 Suppl 1: S159-172. https://doi.org/10.1016/j.jvc.2015.03.009
  6. Gordon SG, Saunders AB, Roland RM, et al. Effect of oral administration of pimobendan in cats with heart failure. J Am Vet Med Assoc 2012; 241: 89-94. https://doi.org/10.2460/javma.241.1.89
  7. Little S. Arterial Thromboembolism. In: The Cat: Clinical Medicine and Management. St. Louis: Elsevier Saunders. 2012: 316-318.
  8. Macgregor JM, Rush JE, Laste NJ, et al. Use of pimobendan in 170 cats (2006-2010). J Vet Cardiol 2011; 13: 251-260. https://doi.org/10.1016/j.jvc.2011.08.001
  9. Reina-Doreste Y, Stern JA, Keene BW, et al. Case-control study of the effects of pimobendan on survival time in cats with hypertrophic cardiomyopathy and congestive heart failure. J Am Vet Med Assoc 2014; 245: 534-539. https://doi.org/10.2460/javma.245.5.534
  10. Smith SA, Tobias AH. Feline arterial thromboembolism: an update. Vet Clin North Am Small Anim Pract 2004; 34: 1245-1271. https://doi.org/10.1016/j.cvsm.2004.05.006
  11. Thompson MF, Scott-Moncrieff JC, Hogan DF. Thrombolytic therapy in dogs and cats. J Vet Emerg Crit Care 2001; 11: 111-121. https://doi.org/10.1111/j.1476-4431.2001.tb00077.x
  12. Welch KM, Rozanski EA, Freeman LM, et al. Prospective evaluation of tissue plasminogen activator in 11 cats with arterial thromboembolism. J Feline Med Surg 2010; 12: 122-128. https://doi.org/10.1016/j.jfms.2009.08.001